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a b s t r a c t
INTRODUCTION: Protein induced by vitamin K absence/antagonist-II (PIVKA-II) is an abnormal protein,
and several reports have demonstrated the efﬁcacy of PIVKA-II in the diagnosis of hepatocellular carci-
noma (HCC).We report an extremely rare case of adenocarcinomaof the colonwith a high serumPIVKA-II
level.
PRESENTATIONOFCASE:A95-year-oldwomanpresentedwith right lowerquadrantpainandappetite loss.
An abdominal computed tomography scan and ultrasonography showed an ascending colon tumor and
multiple metastatic tumors in the liver. The serum level of PIVKA-II was extremely high, 11,900ng/mL.
Colonoscopic examination revealed a tumor accompanied by an ulcer in the ascending colon, which was
highly suspicious for malignancy. Multiple biopsies showed well-differentiated adenocarcinoma of the
colon, which was evaluated as colon cancer, stage IV. PIVKA-II-productive colon cancer was conﬁrmed.
Chemotherapy with TS-1 was administered. The patient died 3 months after initial admission.
DISCUSSION: The expression of PIVKA-II was detected in non-cancer areas, with non-speciﬁc expression
observed in plasma cells in our case. There might be some possibility that hepatoid differentiation exists
in other regions of the colon tumor or in the liver tumor, parenchymal cells or lung metastases, which
were composed of PIVKA-II-positive and AFP-negative cells.
CONCLUSION: To the best of our knowledge, high serum levels of PIVKA-II resulting from colon adeno-
carcinoma have not been reported previously. We report this rare case together with a review of the
literature.
© 2014 The Authors. Published by Elsevier Ltd. on behalf of Surgical Associates Ltd. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
1. Introduction
Protein induced by vitamin K absence or antagonist II (PIVKA-II)
is a newly recognized tumor marker for hepatocellular carcinoma
(HCC) [1]. PIVKA-II has been shown to be a useful and speciﬁc
marker for the diagnosis of HCC. However, PIVKA-II levels may
increase in patients with tumors other than HCC [2]. PIVKA-II-
producing gastric cancer and embryonal carcinoma have been
reported recently [3]. Here, we report a rare case of advanced colon
cancer in a patient with a high serum PIVKA-II level. To the best of
our knowledge, a high serum level of PIVKA-II resulting from colon
adenocarcinoma has not been reported previously.
∗ Corresponding author. Tel.: +81 166 85 2222; fax: +81 166 58 9008.
E-mail address: pippuclinickato@gold.ocn.ne.jp (K. Kato).
2. Presentation of case
A95-year-old Japanesewomanpresentedwith a3-weekhistory
of upper abdominal discomfort, dysphagia, and loss of appetite.
Upon physical examination, a smooth mass measuring 20 cm in
its largest dimension was palpated in the right upper abdomen.
She did not drink and took no medications including warfarin or
antibiotics. At admission, laboratory ﬁndings revealed leukocy-
tosis of 13,200 /mm3; 233U/L aspartate aminotransferase (AST);
32U/Lalanineaminotransferase (ALT);791U/Lalkalinephosphates
(ALP); 440U/L g-glutamyl transferase (GGT); 6.4 g/dl total protein;
and 1.2mg/dL total bilirubin. The level of C-reactive protein (CRP)
was 9.3mg/mL (normal range, 0.5–0.8mg/mL). The serum level of
carcinoembryonic antigen (CEA) was extremely high, 1270ng/mL
(cutoff, 2.5 ng/mL); the-fetoprotein (AFP) level was 2ng/mL (cut-
off of 10ng/mL); and the level of CA 19–9 was extremely high,
http://dx.doi.org/10.1016/j.ijscr.2014.11.072
2210-2612/© 2014 The Authors. Published by Elsevier Ltd. on behalf of Surgical Associates Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).
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Fig. 1. a and b: An abdominal computed tomography (CT) study showed a tumor with a diameter of 6 cm occupying the right upper abdominal quadrant together with
multiple liver lesions (arrow). c: Ultrasonography showed well-deﬁned hypoechoic liver tumors. d: Chest CT scan showed multiple lung lesions.
3070U/mL (cutoff of 37U/mL). The level of PIVKA-II was also
extremely high, 11,900AU/mL(cutoff, 40AU/mL). An abdominal
computed tomography (CT) scan and ultrasonography showed
multiple liver lesions, ascites, and a tumor with a diameter of 6 cm
occupying the right upper abdominal quadrant, but no lymph node
enlargement was identiﬁed (Fig. 1a–c). A chest CT scan showed
multiple lung lesions (Fig. 1d). The colonoscopic examination
revealed a tumor accompanied by a giant ulcer on the ascend-
ing colon (Fig. 2a). Multiple biopsies showed well-differentiated
tubular adenocarcinoma of the colon at stage IV (Fig. 2b). Hepatoid-
differentiated cells were not detected in the biopsy specimens.
Monoclonal antibody raised against PIVKA-II (Eisai, Chiba, Japan)
was used for immunohistochemical analysis, but cancer cells were
not positive for PIVKA-II (Fig. 2c). Non-cancer cells (mainly plasma
cells) were non-speciﬁcally positive (Fig. 2d). An immunohisto-
chemical study showed that CEA- and CA19–9-positive and AFP-
and glypican-3 (GP-3)-negative cells were present in the tumor
(Fig. 3a–d). The patient was administered palliative chemotherapy
with TS-1. The patient died of liver failure 3months after the initial
admission. An autopsy was not performed.
3. Discussion
PIVKA-II is a circulating precursor of prothrombin, which is
found in the blood of patients who are deﬁcient in vitamin K [4].
In 1984, Leibman et al [1]. reported PIVKA-II levels to be signiﬁ-
cantly elevated in HCC patients. The clinical usefulness of PIVKA-II
in the detection of HCC has been demonstrated in many stud-
ies [5,6]. PIVKA-II has been reported to predict the progression
of HCC patients because those with higher PIVKA-II levels had a
signiﬁcantly higher frequency of intrahepatic metastasis, portal or
hepatic vein tumor thrombosis and capsular inﬁltration [7,8]. It is
proposed that PIVKA-II may be useful primarily as a prognostic
biomarker, predicting rapid tumor progression and poorer prog-
nosis [7]. These ﬁndings may be explained by an in vitro study
showing that PIVKA-II stimulates cell proliferation and cell migra-
tion of vascular endothelial cells by binding to the kinase insert
domain receptor, alternatively referred to as vascular endothe-
lial growth factor receptor-2 [9]. The increased production of the
prothrombin precursor in tumor cells, abnormalities in vitamin K-
dependent carboxylation, andvitaminKdeﬁciency in tumor tissues
have been speculated to be the underlyingmechanisms of PIVKA-II
production in HCC [10]. PIVKA-II-producing gastric cancers occur
initially as commongastric adenocarcinoma and the hepatoid com-
ponent arises during tumor progression. The stomach is one of
the most common sites in which hepatoid adenocarcinomas have
been described, the reason for which is unknown. Almost all cases
were with advanced cancers and the hepatoid pattern is observed
in the invasive portion. It has been indicated that the hepatoid-
differentiated foci of the gastric adenocarcinoma may produce the
prothrombin precursor in addition to both AFP and PIVKA-II [2]. It
seems to that the clinicopathological features of PIVKA II-producing
gastric cancer resemble those of AFP-producing gastric cancer,
especially AFP-producing hepatoid adenocarcinoma [11]. The hep-
atoid pattern is often detected histologically, and the production of
PIVKA-II by tumor cells usually is conﬁrmed immunohistochemi-
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Fig. 2. a: The colonoscopic examination revealed a tumor accompanied by a giant ulcer on the ascending colon. b: Multiple biopsies showed a well-differentiated tubular
adenocarcinoma (X 400). c: Immunohistochemical determination of PIVKA-II expression in the area of the adenocarcinoma was negative (X 100). d: Immunohistochemical
determination of PIVKA-II expression in the non-cancer area of plasma cells was non-speciﬁcally positive (X 400).
cally [11]. Hepatoid-differentiated cells are derived from germ cell
tumors located close to the embryonic association of the foregut
endoderm and yolk sac [12]; the foregut derivation of both liver
and stomach and their embryologic proximity likely have a role.
Hepatocellular metaplasia of tumor cells is suggested to be the
mechanism of PIVKA-II production. Carcinomas that histologically
resemble hepatocellular carcinoma (hepatoid adenocarcinomas)
have been described at various sites, including the colon [13].
By contrast, PIVKA-II has been reported to be positive in 26%
of non-cancer tissues adjacent to HCC. The expression of PIVKA-
II in non-cancer tissue adjacent to the HCC is stronger than the
expression in the tumor. The explanation for this phenomenon
might be that accelerated production of the prothrombin precur-
sor in HCC causes a deﬁciency of vitamin K in the local region
surrounding the HCC [14]. It is suggested that non-cancer tis-
sue including liver parenchyma adjacent to the HCC may produce
PIVKA-II [14]. The expression of PIVKA-II was detected in non-
cancer areas, with non-speciﬁc expression observed in plasma cells
inour case.Mosthepatoidadenocarcinomasareassociatedwith the
production of alpha-fetoprotein (AFP), but not all AFP-producing
carcinomas show hepatoid features histologically [15,16]. In our
case, serum AFP level was not high, and hepatoid cells were not
detected in the biopsy specimen. In many gastric cancer cases,
biopsy specimens show only the histological appearance of poorly
or moderately differentiated adenocarcinoma, but hepatoid cells
are detected by the examination of surgical or autopsy materials
[11]. There might be some possibility that hepatoid differentiation
exists in other regions of the colon tumor or in the liver tumor,
parenchymal cells or lung metastases, which were composed of
PIVKA-II-positive and AFP-negative cells.
CA 19–9 has been developed for the diagnosis of digestive
tract malignancies. Recent reports indicated that serum CA19–9
is frequently elevated in subjects with various gastrointestinal
malignancies, suchaspancreatic, colorectal, gastric andhepatic car-
cinomas [17] The antibody has been obtained by immunizing mice
with a human colorectal cell line [18]. The epitope is expressed
on the cell surface as glycolipids and glycoproteins. In patients
with digestive malignancies, the antigen is found in serum, where
it is associated with a high molecular weight carbohydrate-rich
mucin fraction. Serum CA19–9 concentration was most increased
in a patientwith pancreatic cancer or cholangiocarcinoma. CA 19–9
resembles carcinoembryonic antigen in colorectal carcinoma and
various different gastrointestinal adenocarcinomas. Expression of
CA19–9 has been studied in normal andmalignant gastrointestinal
tissues. The antigen was found by immunoperoxidase staining in
40% to 80% of carcinomas from gallbladder, stomach, pancreas, and
colon [19].
The oncofetal antigen glypican 3 (GP 3) is a heparin sulfate pro-
teoglycan that is expressed in more than 70% of HCCs. They are
the ﬁrst transcripts to appear during malignant hepatocyte trans-
formation [20]. An immunohistochemical analysis showed that the
cells present in the colonic lesion were GP3 negative in our case.
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Fig. 3. a and b: Immunohistochemical determination of CEA and CA 19–9 expression in the area of the adenocarcinoma was positive (X 100). c and d: Immunohistochemical
determination of AFP and GP-3 expression in the area of the adenocarcinoma was negative (X 100).
4. Conclusion
We have reported a rare colon cancer in a patient with high
serum levels ofmultiple serum tumormarkers. PIVKA-II-producing
colon cancer is an extremely rare subtype of colon cancer.
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